Boston Scientific Q3 2026 earnings

BSX · 2026-10-28 06:34 BMO ET · 8-K on SEC

Revenue growth decelerated to 1.5% YoY, and GAAP EPS fell 21% YoY to $0.40, driven by a cybersecurity incident.

Headline numbers

MetricActualYoYQoQ8-K location
Revenue$5.138B+1.5%—Ex. 99.1, income statement
EPS (GAAP)$0.40-21.6%—Ex. 99.1, income statement
EPS (adjusted)$0.73-2.7%—Ex. 99.1, income statement
Net income$582M-23.0%—Ex. 99.1, income statement
Adj. EBITDA$1.09B+4.4%—Ex. 99.1, income statement
Adj. EBITDA margin21.2%+1.2 pp—Ex. 99.1, income statement

Revenue breakdown

SegmentActualYoYShare of revenueNote
MedSurg$2.6B+0.6%51%Reported growth
Cardiovascular$2.5B+1.9%49%Reported growth

Margins and costs

  • Gross margin 66.7% (prior 69.9%, change -3.2 pp)
  • Operating expenses $2.600B (+4.4% YoY)
  • One-offs in the quarter Intangible asset impairment charges $39M; Restructuring net charges $63M; Contingent consideration net expense $32M; Litigation-related net charges $81M
  • Effective tax rate 20.9% (prior-year 19.5%, year-to-date 4.5%)
  • Non-GAAP bridge Adds back intangible asset impairment, restructuring, contingent consideration, and litigation-related charges.

KPIs

MetricActualPrior quarterPrior yearChange
U.S. Net sales growth+0.5%+6.2%+6.2%-5.7 pp
EMEA Net sales growth+4.4%+6.1%+6.1%-1.7 pp
APAC Net sales growth(0.6)%+11.2%+11.2%-11.8 pp
LACA Net sales growth+16.0%+22.4%+22.4%-6.4 pp

Guidance

MetricGuidePrior guideChange
Full year 2026 Net sales growth4.25% reported, 3.75% organic5.5 to 6.5% reported, 5 to 6% organic-1.25 to -2.25 pp
Full year 2026 Adjusted EPS$3.16 to $3.18$3.28 to $3.32-0.12 to -0.14
Q4 2026 Net sales(3.0) to (1.0)% reported and organic——
Q4 2026 Adjusted EPS$0.77 to $0.79$0.80 to $0.82-0.03 to -0.03

What drove it

  • Revenue story MedSurg grew 0.6% and Cardiovascular grew 1.9% YoY; U.S. and APAC decelerated, while EMEA and LACA remained strong.
  • EPS story GAAP EPS declined 21.6% YoY to $0.40, while adjusted EPS fell 2.7% to $0.73, reflecting a cybersecurity incident.
  • One-off check Cybersecurity incident impacted operations and financial results.

The good

  • Adjusted EBITDA grew 4.4% YoY to $1.09B
  • Adjusted EBITDA margin expanded 1.2 pp to 21.2%

The bad

  • GAAP net income fell 23.0% YoY to $582M
  • U.S. sales growth decelerated to 0.5% YoY
  • APAC sales declined 0.6% YoY

The ugly

  • Cybersecurity incident caused operational disruption and financial headwinds

Open questions

  • The filing does not quantify the financial impact of the cybersecurity incident.
  • The filing does not provide a reconciliation of adjusted EPS to GAAP EPS.
Full release

Earnings: BSX — filed 2026-10-28

Boston Scientific Corp (BSX) · Form 8-K, Item 2.02 · Filed · SEC filing

Boston Scientific announces results for third quarter 2026

Marlborough, Mass. (October 28, 2026) -- Boston Scientific Corporation (NYSE: BSX) generated net sales of $5.138 billion during the third quarter of 2026, growing 1.5 percent on a reported, operational¹ and organic² basis, all compared to the prior year period. The company reported GAAP net income attributable to Boston Scientific common stockholders of $582 million or $0.40 per share (EPS), compared to $755 million or $0.51 per share a year ago, and achieved adjusted³

EPS of $0.73 for the period, compared to $0.75 a year ago.

"This has been a challenging year for Boston Scientific and I’m proud of how our global teams have responded, particularly to the cybersecurity incident, working with urgency and resilience to restore operations and continue supporting customers and patients," said Mike Mahoney, chairman and chief executive officer, Boston Scientific. "As we move forward, I remain confident in our long-term strategy, fueled by our dedicated talent, differentiated portfolio and strong pipeline of meaningful innovation."

Third quarter financial results and recent developments:

• Reported net sales of $5.138 billion, representing an increase of 1.5 percent on a reported, operational and organic basis, all compared to the prior year period.

• Reported GAAP net income attributable to Boston Scientific common stockholders of $0.40 per share, and achieved adjusted EPS of $0.73 per share.

• Achieved the following net sales growth in each reportable segment, compared to the prior year period:

◦ MedSurg: 0.6 percent reported, 0.7 percent operational and organic

◦ Cardiovascular: 1.9 percent reported, operational and organic

• Achieved the following net sales growth/(decline) in each region, compared to the prior year period:

◦ United States (U.S.): 0.5 percent reported and operational

◦ Europe, Middle East and Africa (EMEA): 4.4 percent reported and 6.1 percent operational

◦ Asia-Pacific (APAC): (0.6) percent reported and (1.1) percent operational

◦ Latin America and Canada (LACA): 16.0 percent reported and 10.5 percent operational

• Commenced enrollment in the Elite AF clinical trial to evaluate the safety and effectiveness of the next-generation

WATCHMAN Elite™ Left Atrial Appendage Closure Device in patients with non-valvular atrial fibrillation who are eligible for anticoagulation therapy to reduce their risk of stroke and who have a rationale to seek a non-pharmacologic alternative.

• Received U.S. Food and Drug Administration (FDA) 510(k) clearance for two technologies within the StoneSmart™ Solutions ecosystem, including the

Navigator™ Flex Ureteral Access Sheath Set, designed to enable the use of suction to remove kidney stone debris, and the

LithoVue™ Elite Single-Use Digital Flexible Ureteroscope with temperature sensing, designed to display real-time fluid temperature alongside ureteroscopy video for procedural monitoring.

• Received U.S. FDA 510(k) clearance for an expanded size offering of the

SEISMIQ™ Intravascular Lithotripsy Peripheral Catheter to treat patients with severely calcified peripheral artery disease both above and below the knee.

• Recognized the American Medical Association's assignment of Category I Current Procedural Terminology (CPT®) codes for renal denervation devices, such as the investigational

TIVUS™ Renal Denervation

System, and implantable tibial nerve stimulation (ITNS) devices, including the eCoin® ITNS System, effective January 2028.

• Entered into a strategic collaboration with

Heartflow, Inc. (Nasdaq: HTFL) to advance AI-powered, computed tomography (CT)-guided planning for percutaneous coronary intervention (PCI) procedures and explore integration of Heartflow's PCI Navigator pre-procedural planning tool and the

AVVIGO™+ Multi-Modality Guidance System.

Financial statements

Income Statement

Three Months Ended September 30, — (Unaudited) (in millions, except per share data)

Three Months Ended September 30, – 2026Three Months Ended September 30, – 2025Nine Months Ended September 30, – 2026Nine Months Ended September 30, – 2025
Net sales5,1385,06515,78414,788
Cost of products sold (excluding amortization expense)1,7101,5234,8944,613
Gross profit3,4283,54210,89010,175
Operating expenses:Selling, general and administrative expenses1,6831,7415,2665,053
Operating expenses:Research and development expenses5205141,5891,483
Operating expenses:Royalty expense12123740
Operating expenses:Amortization expense234225699669
Operating expenses:Intangible asset impairment charges3903946
Operating expenses:Restructuring net charges (credits)63-87485
Operating expenses:Contingent consideration net expense (benefit)-3211-7811
Operating expenses:Litigation-related net charges (credits)81157
Operating expenses:2,6002,4947,7837,387
Operating expenses:Operating income (loss)8281,0483,1072,788
Other income (expense):Interest expense-100-87-285-259
Other income (expense):Other, net4-23133156
Other income (expense):Income (loss) before income taxes7339392,9552,685
Other income (expense):Income tax expense (benefit)153183132463
Other income (expense):Net income (loss)5807552,8232,222
Other income (expense):Net income (loss) attributable to noncontrolling interests-20-6-4
Other income (expense):Net income (loss) attributable to Boston Scientific common stockholders5827552,8302,226
Other income (expense):Net income (loss) per common share - basic0.40.511.931.5
Other income (expense):Net income (loss) per common share - diluted0.40.511.921.49
Weighted-average shares outstandingBasic1,448.71,481.71,4681,479.6
Weighted-average shares outstandingDiluted1,4521,495.51,473.91,494

1. Operational net sales growth excludes the impact of foreign currency fluctuations.

2. Organic net sales growth excludes the impact of foreign currency fluctuations and net sales attributable to certain acquisitions and divestitures for which there are less than a full period of comparable net sales.

3. Adjusted EPS excludes the impact of certain charges (credits) as defined below within the "Use of Non-GAAP Financial Measures" section.

Net sales for the third quarter by business and region:

Guidance for Full Year and Fourth Quarter 2026

The company now estimates net sales growth for the full year 2026, versus the prior year period, to be approximately 4.25 percent on a reported basis and approximately 3.75 percent on an organic basis. Full year organic net sales guidance excludes the impact of foreign currency fluctuations and net sales attributable to certain acquisitions and divestitures for which there are less than a full period of comparable net sales. The company now estimates adjusted EPS, excluding certain charges (credits), of $3.16 to $3.18.

The company estimates net sales to decline in the fourth quarter of 2026, versus the prior year period, by approximately (3.0) to (1.0) percent on a reported and organic basis. Fourth quarter organic net sales guidance excludes the impact of foreign currency fluctuations and net sales attributable to certain acquisitions and divestitures for which there are less than a full period of comparable net sales. The company estimates adjusted EPS, excluding certain charges (credits), of $0.77 to $0.79.... (truncated)inancial results.

Conference Call Information

Boston Scientific management will be discussing these results with analysts on a conference call today at 8:00 a.m. ET. The company will webcast the call to interested parties through its website: investors.bostonscientific.com. Please see the website for details on how to access the webcast. The webcast will be available for approximately one year on the Boston Scientific website.

About Boston Scientific

Boston Scientific transforms lives through innovative medical technologies that improve the health of patients around the world. As a global medical technology leader for more than 45 years, we advance science for life by providing a broad range of high-performance solutions that address unmet patient needs and reduce the cost of healthcare. Our portfolio of devices and therapies helps physicians diagnose and treat complex cardiovascular, respiratory, digestive, oncological, neurological and urological diseases and conditions. Learn more at www.bostonscientific.com and follow us on

LinkedIn.

Cautionary Statement Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements may be identified by words like "anticipate," "expect," "project," "believe," "plan," "estimate," "may," "intend" and similar words. These forward-looking statements are based on our beliefs, assumptions and estimates using information available to us at the time and are not intended to be guarantees of future events or performance. These forward-looking statements include, among other things, statements regarding our expected net sales; reported, operational and organic revenue growth rates; adjusted EPS for the fourth quarter and full year 2026; our financial performance; impacts of the August 2026 cybersecurity incident; acquisitions; clinical trials; our business plans and product performance; and new and anticipated product approvals and launches. If our underlying assumptions turn out to be incorrect, or if certain risks or uncertainties materialize, actual results could vary materially from the expectations and projections expressed or implied by our forward-looking statements. These factors, in some cases, have affected and in the future (together with other factors) could affect our ability to implement our business strategy and may cause actual results to differ materially from those contemplated by the statements expressed in this press release. As a result, readers are cautioned not to place undue reliance on any of our forward-looking statements.

Risks and uncertainties that may cause such differences include, among other things: economic conditions, including the impact of foreign currency fluctuations; future U.S. and global political, competitive, reimbursement and regulatory conditions, including changing trade and tariff policies; geopolitical conflicts and tensions; manufacturing, distribution and supply chain disruptions and cost increases; disruptions caused by cybersecurity events, including the impacts of the cybersecurity incident first reported on August 26, 2026 on our operations and financial results; disruptions caused by public health emergencies or extreme weather or other climate change-related events; labor shortages and increases in labor costs; variations in outcomes of ongoing and future clinical trials and market studies; new product introductions and the market acceptance of those products; market competition for our products; expected pricing environment; expected procedural volumes; the closing and integration of acquisitions; demographic trends; intellectual property rights; litigation; financial market conditions; the execution and effect of our prior and new restructuring programs; the execution and effect of our business strategy, including our cost-savings and growth initiatives; our ability to achieve sustainability goals; and future business decisions made by us and our competitors. New risks and uncertainties may arise from time to time and are difficult to predict. All of these factors are difficult or impossible to predict accurately and many of them are beyond our control. For a further list and description of these and other important risks and uncertainties that may affect our future operations, see Part I, Item 1A. Risk Factors in our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, which we may update in Part II, Item 1A. Risk Factors in Quarterly

Reports on Form 10-Q we have filed or will file hereafter. We disclaim any intention or obligation to publicly update or revise any forward-looking statements to reflect any change in our expectations or in events, conditions, or circumstances on which those expectations may be based, or that may affect the likelihood that actual results will differ from those contained in the forward-looking statements, except as required by law. This cautionary statement is applicable to all forward-looking statements contained in this press release.

Note

: Amounts reported in millions within this press release are computed based on the amounts in thousands. As a result, the sum of the components reported in millions may not equal the total amount reported in millions due to rounding. Certain columns and rows within tables may not add due to the use of rounded numbers. Percentages presented are calculated from the underlying unrounded amounts.

Use of Non-GAAP Financial Information

A reconciliation of the company's non-GAAP financial measures to the corresponding GAAP measures, and an explanation of the company's use of these non-GAAP financial measures, is included in the exhibits attached to this press release.

Earlier releases

From SEC EDGAR. Analysis by Pear Digitals from the filing alone. Not investment advice. · Latest earnings · Markdown

Screener

Plans

Premium and Pro coming soon.

Log in

New here?

Join the waitlist

Pear FMV opens to everyone soon. We'll email you when it does.